Compare REKR & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REKR | ANIX |
|---|---|---|
| Founded | 2017 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 100.7M |
| IPO Year | 2017 | 2013 |
| Metric | REKR | ANIX |
|---|---|---|
| Price | $0.69 | $3.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | ★ 2.2M | 278.9K |
| Earning Date | 05-13-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.35 | ★ 12.82 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,234,000.00 | $210,000.00 |
| Revenue This Year | $12.51 | N/A |
| Revenue Next Year | $23.49 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.60 | $2.32 |
| 52 Week High | $3.42 | $5.46 |
| Indicator | REKR | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 56.35 |
| Support Level | $0.60 | $2.90 |
| Resistance Level | $0.74 | $3.09 |
| Average True Range (ATR) | 0.04 | 0.26 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 67.41 | 62.43 |
Rekor Systems Inc is a roadway intelligence company focused on modernizing public safety, urban mobility, and transportation management through solutions. The company delivers services and solutions that collect, connect, and organize mobility data, providing real-time insights to support decision making, enhance situational awareness, enable rapid response, and support predictive analytics. The Company derives its revenues mainly from the licensing and sale of its roadway data and traffic management product and service offerings. These offerings include a mixture of data collection, implementation, engineering, customer support, and maintenance services, as well as software and hardware. The company operates in the United States and other regions.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.